

## A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

### SUPPLEMENTARY MATERIALS

**Supplementary Table 1: Circulating tumor cell favorable and conversion rate**

	ARM A N=41	ARM B N=44	P Value
Circulating Tumor Cell (CTC)			
Baseline			
N	39	40	
Median	5	4.5	
Range	0-139	0-253	0.65
Favorable (< 5 CTC/7.5 mL)	17 (41.5)	20 (45.5)	
Unfavorable (≥5 CTC/7.5 mL)	22 (53.7)	20 (45.5)	
Missing	2 (4.9)	4 (9.1)	
At 6 weeks			
Favorable (< 5 CTC/7.5 mL)	23 (56.1)	28 (63.6)	0.42
Unfavorable (≥5 CTC/7.5 mL)	11 (26.8)	8 (18.2)	
Missing	7 (17.1)	8 (18.2)	
At 12 weeks			
Favorable (< 5 CTC/7.5 mL)	22 (53.7)	25 (56.8)	0.55
Unfavorable (≥5 CTC/7.5 mL)	9 (22.0)	6 (13.6)	
Missing	10 (24.4)	13 (29.5)	
Conversion from unfavorable to favorable			
At 6 weeks	7 (17.1)	10 (22.7)	0.59
At 12 weeks	7 (17.1)	9 (20.5)	0.79